Taysha Gene Therapies is a highly focused, clinical-stage biotechnology company that has transitioned into a single-asset play centered on TSHA-102, an intrathecally delivered AAV9 gene therapy for Rett syndrome. Following the strategic discontinuation of its broader pipeline to conserve capital, Taysha has successfully secured a robust cash runway extending into 2028. TSHA-102 utilizes a proprietary miRARE auto-regulatory element to prevent MeCP2 overexpression, addressing a critical safety hurdle that has historically limited Rett syndrome gene therapies. Early clinical data from the REVEAL Phase 1/2 trials has demonstrated a 100% response rate with zero treatment-related serious adverse events or dose-limiting toxicities. Crucially, the FDA has aligned on an accelerated pathway that allows Taysha to skip Phase 3 and submit a Biologics License Application (BLA) based on a 6-month interim analysis of the ongoing REVEAL pivotal trial. With pivotal data expected in late 2026, Taysha represents a high-conviction, catalyst-driven investment opportunity with a clear path to commercialization by 2027/2028.